Considering that cancer cells often down-regulate MHC I expression and up-regulate ligands for NK cell activating receptors during the immunoediting process, NK cells can effectively recognize cancer cells and subsequently undergo activation to generate robust anticancer immune responses in synergistic and/or complementary action with CTLs [18,36]. This evidence concerns the gene NCR1 and cancer.